Literature DB >> 25098860

Warfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare fee-for-service enrollees.

Xinggang Liu1, Mona Baumgarten, Gordon Smith, Steven Gambert, Stephen Gottlieb, Gail Rattinger, Jennifer Albrecht, Patricia Langenberg, Ilene Zuckerman.   

Abstract

This study examined warfarin usage for elderly Medicare beneficiaries with atrial fibrillation (AF) who suffered traumatic brain injury (TBI), hip fracture, or torso injuries. Using the 5% Chronic Condition Data Warehouse administrative claims data, this study included fee-for-service Medicare beneficiaries who had a single injury hospitalization (TBI, hip fracture, or major torso injury) between 1/1/2007 and 12/31/2009, with complete Medicare Parts A, B (no Medicare Advantage), and D coverage 6 months before injury, and who were aged 66 years or older and diagnosed with AF at least 1 year before injury. About 45% of the AF patients were using warfarin before TBI or torso injury, and 35% before hip fracture. After injury, there was a dramatic and persistent decrease in warfarin use in TBI and torso injury groups (30% for TBI and 37% for torso injury at 12 months after injury). Warfarin usage in hip fracture patients also dropped after injury but returned to pre-injury level within 4 months. TBI and torso injury lead to significant decreases in warfarin usage in elderly AF patients. Further research is needed to understand reasons for the pattern and to develop evidence-based management strategies in the post-acute setting.
© 2014, The American College of Clinical Pharmacology.

Entities:  

Keywords:  stroke; traumatic injury; warfarin

Mesh:

Substances:

Year:  2014        PMID: 25098860      PMCID: PMC4570827          DOI: 10.1002/jcph.375

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  24 in total

1.  Pharmacologic thromboprophylaxis is a risk factor for hemorrhage progression in a subset of patients with traumatic brain injury.

Authors:  Andrew Stewart Levy; Kristin Salottolo; Raphael Bar-Or; Patrick Offner; Charles Mains; Michael Sullivan; David Bar-Or
Journal:  J Trauma       Date:  2010-04

2.  Optimal timing of resumption of warfarin after intracranial hemorrhage.

Authors:  Ammar Majeed; Yang-Ki Kim; Robin S Roberts; Margareta Holmström; Sam Schulman
Journal:  Stroke       Date:  2010-10-28       Impact factor: 7.914

3.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Prophylaxis for venous thromboembolism during rehabilitation for traumatic brain injury: a multicenter observational study.

Authors:  Mary Carlile; David Nicewander; Stuart A Yablon; Allen Brown; Robert Brunner; David Burke; Heechin Chae; Jeffrey Englander; Steve Flanagan; Flora Hammond; Allen Khademi; Lisa A Lombard; Jay M Meythaler; W Jerry Mysiw; Ross Zafonte; Ramon Diaz-Arrastia
Journal:  J Trauma       Date:  2010-04

5.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

6.  National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries.

Authors:  Mukaila A Raji; Matthew Lowery; Yu-Li Lin; Yong-Fang Kuo; Jacques Baillargeon; James S Goodwin
Journal:  Ann Pharmacother       Date:  2013-01-16       Impact factor: 3.154

Review 7.  Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Gary Gronseth; David C Anderson; José Biller; Brett Cucchiara; Rima Dafer; Larry B Goldstein; Michael Schneck; Steven R Messé
Journal:  Neurology       Date:  2013-05-28       Impact factor: 9.910

8.  A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study.

Authors:  Herb A Phelan; Steven E Wolf; Scott H Norwood; Kim Aldy; Scott C Brakenridge; Alexander L Eastman; Christopher J Madden; Paul A Nakonezny; Lisa Yang; David P Chason; Gary M Arbique; John Berne; Joseph P Minei
Journal:  J Trauma Acute Care Surg       Date:  2012-12       Impact factor: 3.313

9.  National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation.

Authors:  Margaret C Fang; Randall S Stafford; Jeremy N Ruskin; Daniel E Singer
Journal:  Arch Intern Med       Date:  2004-01-12

10.  The development and feasibility of a remote damage control resuscitation prehospital plasma transfusion protocol for warfarin reversal for patients with traumatic brain injury.

Authors:  Martin D Zielinski; Dustin L Smoot; James R Stubbs; Donald H Jenkins; Myung S Park; Scott P Zietlow
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.337

View more
  1 in total

1.  Metabolomics and Precision Medicine in Trauma: The State of the Field.

Authors:  Sudha P Jayaraman; Rahul J Anand; Jonathan H DeAntonio; Martin Mangino; Michel B Aboutanos; Vigneshwar Kasirajan; Rao R Ivatury; Alex B Valadka; Olena Glushakova; Ronald L Hayes; Lorin M Bachmann; Gretchen M Brophy; Daniel Contaifer; Urszula O Warncke; Donald F Brophy; Dayanjan S Wijesinghe
Journal:  Shock       Date:  2018-07       Impact factor: 3.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.